Anamorelin
ANAMORELIN is a novel once-daily, orally active ghrelin receptor agonist indicated for the treatment of cancer cachexia in patients suffering from malignant tumors of non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer or colorectal cancer. Cancer cachexia is a complex metabolic disorder syndrome, characterized by decreased body weight (especially decreased muscle mass) and anorexia associated with cancer. It has been well documented that cancer cachexia causes a significant impact on patients’ quality of life (QOL) and prognosis.
Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Cancer Anorexia-Cachexia in NSCLC patients
TG-C [TissueGene-C]
TG-C [TissueGene-C] is a first-in-class cell-mediated gene therapy targeting osteoarthritis (OA) of the knee through a single intra-articular injection. Clinical trials held in the United States and abroad have demonstrated pain relief and increased mobility, as well indicators towards decreased progression of OA and improvements in joint structure. The allogeneic cell therapy product could provide an alternative to traditional treatment and surgery, or delay the progression of OA to minimize the need for multiple surgical interventions. The TG-C cell therapy product is being developed in two dosages: TG-C developed in the United States by Kolon TissueGene and TG-C LD developed in Korea by Kolon Life Science.
